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A B S T R A C T
Liquid chromatography tandem mass spectrometry (LC-MS/MS) assays are considered the reference standard for
serum steroid hormone analyses, while full urinary steroid proﬁles are only achievable by gas chromatography
(GC–MS). Both LC-MS/MS and GC–MS have well documented strengths and limitations. Recently, commercial
ultra-high performance supercritical ﬂuid chromatography–tandem mass spectrometry (UHPSFC-MS/MS) sys-
tems have been developed. These systems combine the resolution of GC with the high-throughput capabilities of
UHPLC. Uptake of this new technology into research and clinical labs has been slow, possibly due to the per-
ceived increase in complexity. Here we therefore present fundamental principles of UHPSFC-MS/MS and the
likely applications for this technology in the clinical research setting, while commenting on potential hurdles
based on our experience to date.
1. Introduction
Steroid hormones play an essential role in normal physiological
function regulating a range of processes including metabolism, in-
ﬂammation, immune function, salt and water balance, stress manage-
ment, and reproduction. Abnormal production or metabolism of steroid
hormones results in a wide array of endocrine conditions including, but
not limited to, Cushing's syndrome, hyperaldosteronism, congenital
adrenal hyperplasia (CAH), disorders of sexual development (DSD) and
polycystic ovary syndrome (PCOS) [1]. The accurate quantiﬁcation of
steroid hormones is therefore vital for both research into these condi-
tions as well as for diagnostic and monitoring purposes. These mea-
surements are, however, complex due to the similar structure shared by
all steroid hormones, precursors and metabolites. Mass spectrometry
(MS) based approaches in the form of either gas chromatography–mass
spectrometry (GC–MS) or liquid chromatography tandem mass spec-
trometry (LC-MS/MS) are currently regarded as the most accurate
methods for steroid quantiﬁcation [2,3]. Unlike immunoassay techni-
ques which are hampered by cross-reactivity, MS based methods allow
for accurate measurements and the simultaneous quantiﬁcation of
multiple steroids [4]. As a result, there is currently a drive within the
endocrine community to phase out immunoassays in favour of
validated MS methods. Both GC–MS and LC-MS/MS have speciﬁc
strengths and limitations making the choice between them dependent
on the speciﬁc application. There is now the possibility of a third option
in the form of ultra-high performance supercritical ﬂuid chromato-
graphy-tandem mass spectrometry (UHPSFC-MS/MS). Although su-
percritical ﬂuid chromatography (SFC) has been around since the
1960s, this technique has not found wide spread appeal due to nu-
merous technical challenges associated with the use of supercritical
ﬂuids. Recent advances in technology have resulted in the development
of commercial UHPSFC systems, which can potentially combine the
strengths of both LC and GC, while at the same time eliminating the
drawbacks of each. Arthur C. Clarke once wrote that “any suﬃciently
advanced technology is indistinguishable from magic”. We therefore
present the basic principles of UHPSFC-MS/MS to the reader as to make
this technology understandable and accessible. Furthermore, we discuss
the potential use of UHPSFC-MS/MS within the clinical setting as an
alternative to LC-MS/MS and GC–MS, while at the same time presenting
the hurdles that remain to be overcome.
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2. Strengths and limitation of current MS based assays in the
clinical laboratory
2.1. GC–MS
GC–MS achieves excellent resolution and sensitivity, and has rou-
tinely been employed for the analysis of urinary steroid metabolite
proﬁles in patients with suspected inborn steroidogenic disorders in-
cluding the variants of CAH (21-hydroxylase deﬁciency, 17α-hydro-
xylase deﬁciency, 11β-hydroxylase deﬁciency, 3β-hydroxysteroid de-
hydrogenase type 2 deﬁciency, P450 oxidoreductase deﬁciency), and of
other inborn steroidogenic disorders (e.g. 5α-reductase type 2 deﬁ-
ciency, hexose-6-phosphate dehydrogenase deﬁciency and cortisone
reductase deﬁciency) [5–7]. GC–MS has also been used for prenatal
screening of selected disorders using maternal urine samples [8]. In
paediatrics, GC–MS is highly valued for diagnosing these rare disorders
with high diagnostic sensitivity and speciﬁcity. GC–MS is also con-
sidered the mainstay discovery tool in clinical steroid investigations
[5]. The advent of GC–MS/MS has further improved this cornerstone
technique resulting in improvements in limits of quantitation, signal to
noise and linear range [9]. Nonetheless, urine analysis by GC remains
cumbersome, as it requires laborious sample preparation including
enzymatic deconjugation and derivatisation, as well as solid phase and/
or liquid/liquid extractions [10]. This technique is therefore expensive
and time-consuming and not applicable to high-throughput assays. The
time required for a result to be obtained (5–7 days) together with small
batch sizes per run mean there are associated high running costs and
thus preclude the use of GC–MS for screening of larger patient popu-
lations or use for routine monitoring purposes. Moreover, GC–MS
cannot be used to quantify intact steroid conjugates (sulphates/glu-
curonides) as a deconjugation step is mandatory prior to derivatisation
[3]. This obligatory deconjugation introduces the potential for in-
complete deconjugation or derivatisation, as well as the potential for
unwanted modiﬁcations during the hydrolysis step. Furthermore, no
information pertaining to the position of the conjugate is obtainable
[11–13] Bi-sulphated steroids and gluco-sulpho steroids are also not
fully deconjugated and therefore not detected.
2.2. LC-MS/MS
Unlike GC–MS, the strength of LC-MS/MS is the speciﬁc and sensi-
tive high-throughput analysis of several analytes [14,15]. In most cases,
LC-MS/MS does not require sample derivatisation and sample pre-
paration is typically less complex than required for GC–MS. Further-
more, ultra-high performance liquid chromatography (UHPLC) in-
strumentation oﬀer signiﬁcantly reduced runtimes compared to
traditional LC, making high throughput assays possible. This technique
is routinely used for the quantiﬁcation of selected panels of serum
steroids within clinical laboratories and is preferred to immuno-based
assays, which are subject to cross reactivity [16]. The main drawback
with short high-throughput runs is that the number of analytes that can
be resolved and quantiﬁed is limited. Nonetheless, improved resolution
of comprehensive steroid panels is achievable by longer chromato-
graphic runs, which are common requirements for GC–MS methods. It
should be noted that LC-MS/MS is prone to ion suppression (or en-
hancement) due to matrix eﬀects. Additionally some classes of steroids,
e.g. Δ5 and 5α/β-reduced steroids, ionise poorly resulting in inadequate
limits of quantiﬁcation [3]. Sensitivity of diﬃcult to analyse steroids
such as dehydroepiandrosterone (DHEA) and 5α-dihydrotestosterone
(DHT) is improved signiﬁcantly by derivatisation, but can result in in-
creased chromatographic complexity due to the production of multiple
derivative isomers [10,17]. For example, the derivatisation of the ke-
tone group in DHEA to form DHEA-oxime improves mass spectrometry
sensitivity tenfold, but produces multiple derivatives for other serum
steroids such as cortisol and DHT, thus requiring further chromato-
graphic optimisation [18,19]. Steroid conjugates can easily be
quantiﬁed by LC-MS/MS, thereby making the quantiﬁcation of steroids
undetectable by GC–MS possible [3,20,21].
3. Considerations for the use of UHPSFC-MS/MS in the clinical
laboratory
3.1. Introduction to UHPSFC-MS/MS
To cover all aspects of steroid metabolism, the steroid research la-
boratory should employ both LC-MS/MS and GC–MS as complimentary
instruments [3]. The recent advent of commercial UHPSFC systems
may, however, oﬀer an alternative as UHPSFC combines many of the
strengths of both GC and LC. SFC is itself not a new technique and was
used for steroid analysis almost 30 years ago [22]. The ﬁrst SFC-MS
experiments were conducted by Tuomola et al., looking at androste-
none in pig fat following a simple dichloromethane extraction [23].
Today SFC can be coupled to the highly sensitive, fast scanning mass
spectrometer, allowing multiple low level steroids to be quantiﬁed in a
single method [24]. For a comprehensive review of SFC see [2–4].
UHPSFC works through the combination of multiple solvent systems
and pressure regulators. Highly miscible supercritical CO2 is used as the
primary mobile phase, which has liquid-like densities and dissolving
capacities, but demonstrates high gas-like diﬀusivity and low viscosities
thereby allowing for enhanced chromatographic eﬃciency and resolu-
tion [25,26]. Commercial UHPSFC systems make use of liquid organic
modiﬁers of diﬀerent polarities, which when combined with the su-
percritical CO2 and wide range of stationary phases results in un-
paralleled versatility and selectivity [26–28]. This makes UHPSFC ideal
for separating compounds with similar structures and similar mass
spectra, such as steroids. While the addition of an organic modiﬁer does
technically prevent the CO2 from achieving the supercritical state, the
term UHPSFC is maintained as the subcritical CO2 demonstrates the
same advantageous mobile phase properties [29]. A back-pressure
regulator is an essential component of UHPSFC systems as this prevents
the decompression of the supercritical CO2 during chromatographic
separation (Fig. 1). While conventional UHPLC systems require a high
ﬂow rates to achieve reduced run times, the high ﬂow rates can inhibit
desolvation and suppress ionisation and therefore reduce the sensitivity
of the MS [30]. During UHPSFC-MS/MS, the CO2 decompresses fol-
lowing the post-column regulator, thereby substantially minimising the
need for desolvation at the electrospray ionisation (ESI) source and
enhancing ionisation. In fact, the decompression is so comprehensive,
especially during conditions of low modiﬁer content (< 5%) that the
post-column addition of solvent is required to avoid analyte
Fig. 1. Schematic illustrating the key elements of a UHPSFC-MS/MS system.
BPR, back pressure regulator.
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precipitation. This post-column solvent is referred to as the make-up
and is provided by an independent make-up pump (Fig. 1). In addition
to preventing precipitation the make-up can also be used to aid ioni-
sation.
An obvious advantage of this set up is that the modiﬁer can be
optimised to aid separation, while the make-up solvent and ﬂow rate
can be optimised independently to allow for optimal ionisation, thereby
improving sensitivity, while having no inﬂuence on the selectivity
achieved by the UHPSFC system [27,31]. Indeed, increases in sensi-
tivity due to enhanced desolvation have been observed in studies
comparing UHPLC-MS/MS to UHPSFC-MS/MS, though interestingly
these eﬀects were more pronounced in older generation triple quad-
rupole devices [27]. One possible explanation for this observation is
that UHPSFC-MS/MS primarily makes use of organic solvents as both
the modiﬁer and make-up solvent and these are more susceptible to
desolvation than water, which often forms a substantial percentage of
the mobile phase used in UHPLC-MS/MS. Newer mass spectrometers
may, however, be more compatible with highly aqueous mobile phases,
thereby negating some of this advantage [27,32]. Although the obvious
technical beneﬁts of UHPSFC-MS/MS are clear, the implementation of
any new technology is not without its challenges. We therefore discuss
both the potential strength of the technique while at the same time
commenting on potential hurdles.
3.2. Orthogonal chromatography – it's not a black box
The majority of clinicians and scientists working with steroid ana-
lyses are familiar with the elution order of steroids achieved by GC and
UHPLC. With GC elution order denoted by volatility of the derivatives
in the gas phase, combined with interactions within the capillary
column. UHPLC and older LC methods make use of reverse phase
chromatography in which separation is achieved based on polarity.
Although UHPSFC is compatible with both normal and reversed phase
columns, the retention mechanism is primarily based on hydrogen
bonding and dipole-dipole interactions which oﬀers an alternate, or-
thogonal selectivity [33]. This was recently illustrated when we
compared the elution order of nineteen steroids by UHPLC and UHPSFC
[24]. UHPLC with a reverse phase column clearly separated the steroids
primarily based on polarity, with the more polar compounds eluting
ﬁrst. Conversely, separation of the same steroids by UHPSFC with a
normal phase column did not yield the inverse elution sequence as
might be expected for a normal phase column, but instead yielded a
scrambled elution sequence that did not correlate to the results
achieved by UHPLC. Although this elution order might be less intuitive
to understand or predict, especially for those familiar with conventional
reverse phase chromatography, a basic understanding of the retention
mechanism can shed light on what might ﬁrst appear to be a black box.
This is illustrated well in the following example [24]. When six closely
related C19 steroids were separated by conventional reverse-phase
UHPLC-MS/MS the steroids grouped well by polarity (Fig. 2). Andros-
tenedione (A4) and testosterone (T) both contain two oxygen atoms in
the form of either keto or hydroxyl groups. These steroids were the least
polar and were well retained by the column. The four 11‑oxygentated
steroids, 11β-hydroxyandrostenedione (11OHA4), 11-ketoan-
drostenedione (11KA4), 11β-hydroxytestosterone (11OHT) and 11-ke-
totestosterone (11KT) all contain three oxygen atoms resulting in the
earlier elution of these four steroids which also grouped together based
on the hydrophobic interactions of the steroids with the C18 carbon
chain of the stationary phase. It should, however, be noted that while
polarity due to this hydrophobic eﬀect drives the distinct groupings,
other factors play a role in determining the elution order within the
groupings. It is clear from Fig. 2 below that within the groupings the
steroids containing more keto groups elute before those with more
hydroxyl groups. This may be counterintuitive as keto groups are less
polar than hydroxyl groups, however, one must take the column
chemistry into account. In this case separation was achieved using a
High Strength Silica column (HSS) with T3 end-capping, a propriety
method used by Waters. The earlier elution of steroids containing a
higher proportion of less polar keto groups is likely due to electrostatic
repulsion between the keto group and the oxysilane oxygen in the end
cap. In this case the separation achieved by reverse-phase UHPLC can
therefore be explained by a combination of hydrophobic eﬀects (due to
Fig. 2. Schematic illustrating the diﬀerent separation chemistries for UHPLC and UHPSFC. During UHPLC the analytes are separated primarily based on polarity with
the more polar steroids (1–4) grouping together and the less polar steroids (5 and 6) also forming a distinct grouping. During UHPSFC an orthogonal separation is
observed, and three distinct groupings are observed based on hydrogen bonding potential of the steroids. Steroids: 11-ketoandrostenedione (1), 11-ketotestosterone
(2), 11β-hydroxyandrostenedione (3), 11β-hydroxytestosterone (4), androstenedione (5) and testosterone (6).
Figure modiﬁed from [13].
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diﬀerences in polarity) and electrostatic repulsion.
The scattered elution order obtained by separating the same six
steroids by UHPSFC-MS/MS with a normal phase 2-ethylpyridine
column can be explained by their hydrogen-bonding potential. In this
instance the hydroxyl groups can act as hydrogen bond donors with the
stationary phase providing the acceptor. Steroids with more hydroxyl
groups are therefore retained longer on the column. A4 therefore elutes
ﬁrst (two keto groups), followed by 11KA4 (three keto groups). These
are followed by T (one keto and one hydroxyl), 11OHA4 (two ketos,
one hydroxyl), 11KT (two ketos, one hydroxyl) and 11OHT (one keto,
two hydroxyls). The separation of compounds with the same number of
functional groups, such as 11OHA4 and 11KT, is dependent on the lo-
cation of the groups as well as additional dipole-dipole interactions.
Organic modiﬁers and additives such as ammonium formate can act as
hydrogen bond donors and/or acceptors and compete for hydrogen
bonds with the stationary phase, which is accomplished by im-
plementing a gradient from a low to high (40–50%) modiﬁer content.
It should be noted that other column chemistries may include hy-
drogen bond donors or a combination of donors and acceptors and
would therefore allow for altered selectivity. Available column che-
mistries include: Ethylene-Bridged Hybrid (BEH), BEH 2-Ethylpyridine
(2-EP), Charged-Surface Hybrid Fluoro-Phenyl (PFP), High Density Diol
(Diol), 2-Picolylamine (2-PIC), Diethylamine (DEA), 1-
Aminoanthracene (1-AA) and Amylose-tris-(3,5-dimethylphenylcarba-
mate) (AMY1), among others. The advantage of this orthogonal tech-
nique is therefore the wide range of selectivity which is achieved by the
compatibility of supercritical CO2 with multiple organic solvents and
column chemistries [26]. This makes it possible to separate steroids of
similar polarities, which may not be easy to separate by UHPLC [24].
Furthermore, from our experience to date, isomers such as such as 11-
ketoandrosterone and 11-ketoepiandrosterone are separated with re-
lative ease [24]. This may be particularly useful for the high-
throughput quantiﬁcation of urinary steroids, which contain numerous
isomers. While we have previously made use of the 2-EP column for the
separation of androgens [24], preliminary screening of urinary steroids
has shown that the Diol column may oﬀer the best selectivity for this
application. This is in agreement with a study which developed a
screening method for doping agents, including anabolic steroids, in
urine [33]. Another study has successfully demonstrated the separation
of sulphated and glucuronidated steroids using 2-EP and BEH columns,
respectively and included multiple sets of isomers [13].
3.3. Matrix eﬀects
The coelution of substances extracted from the sample matrix with
an analyte can alter the ionisation eﬃciency of the analyte, resulting in
either signal enhancement or suppression [34]. These so called “matrix
eﬀects” therefore remain an important consideration during the de-
velopment and validation of any mass spectrometry based analytical
method. To date, few studies have compared matrix eﬀects between
UHPLC-MS/MS and UHPSFC-MS/MS methods and this area therefore
requires substantially more work. Nonetheless, results to date suggest
matrix eﬀects are of an acceptable level or even reduced in UHPSFC-
MS/MS [24,32,33,35]. When comparing matrix eﬀects between
UHPLC-MS/MS and UHPSFC-MS/MS on the quantiﬁcation of 43 ana-
bolic compounds, including anabolic steroids, from urine, Desfontaine
et al. observed that UHPSFC-MS/MS resulted in substantially milder
matrix eﬀects for most compounds tested. They suggest that this phe-
nomenon is a result of the diﬀerences in mechanisms associated with
extraction and chromatography. Steroid extractions usually make use of
solid phase extraction (SPE), supported liquid extraction (SLE) or li-
quid-liquid extraction techniques, which are all based on partition
mechanism during which analytes are separated by polarity. It is
therefore not surprising that during UHPLC-MS/MS, extracted matrix
components often coelute with the analyte as this technique also se-
parates the analytes based on polarity, most often using reverse-phase
chromatography. Conversely, UHPSFC-MS/MS makes use of a diﬀerent
retention mechanism in which separation is accomplished primarily
based on hydrogen bonding and dipole-dipole interactions, thus re-
sulting in the greater likelihood of separating extracted matrix com-
ponents from the analyte of interest [35]. UHPSFC-MS/MS therefore
oﬀers the potential to reduce matrix eﬀects, however, more investiga-
tions are required for complex matrices such as serum.
3.4. Is sample loss due to the splitter a problem?
One of the biggest concerns expressed by clinicians or research
scientists alike when learning about UHPSFC-MS/MS is the potential
loss or dilution of sample due to the splitter (Fig. 1). The splitter is
required to direct a substantial portion of the column eﬄuent to the
back-pressure regulator, which is an essential component of commer-
cial UHPSFC systems. Only the remaining eﬄuent is directed towards
the MS interface. A large concern is then that valuable analytes are in
fact directed away from the MS and that this causes a decrease in
sensitivity. This is indeed the case when using mass-ﬂow sensitive io-
nisation techniques such as atmospheric-pressure chemical ionisation
(APCI). Comprehensive testing coupled to modelling revealed that the
split ratio is dependent on the chromatographic conditions, including
the ﬂow rate and percentage modiﬁer, as well as the back-pressure
settings and the ﬂow rate of the make-up solvent. Split ratios between 2
and 12 were observed depending on settings and resulted in propor-
tional losses in sensitivity, though losses were limited to 1 order of
magnitude [29]. Unlike APCI, ESI is a concentration-dependent ioni-
sation technique. Although it may not be intuitive, the split ratio be-
tween the back-pressure regulator and MS does not inﬂuence sensitivity
when using ESI as the amount of analyte lost to the back-pressure
regulator is directly proportional to the amount of solvent lost and thus
the concentration of the analyte directed towards the MS remains un-
changed. The addition of make-up solvent does, however, dilute the
analyte thereby reducing sensitivity, but comprehensive analysis has
shown that this dilution factor is minimal (1.1 to 1.5) under typical
conditions [29]. Therefore, although the concept of the splitter is dif-
ﬁcult to come to terms with, especially when considering valuable
clinical samples which may contain only very low levels of speciﬁc
analytes, the real-world losses when using ESI are minimal. Further-
more, the increased sensitivity due to the enhanced desolvation which
is achieved during UHPSFC-MS/MS seem to far outweigh any losses due
to the splitter.
3.5. Robust sensitivity
As already mentioned a real strength of UHPSFC-MS/MS is an in-
crease in sensitivity due to improved desolvation. We have previously
demonstrated increases in sensitivity of 5-fold for the diﬃcult to ionise
steroid, DHT, and up to increases up to 50-fold for easily ionisable
steroids such as T and A4 [24]. The reported increases were all despite
10-fold lower injection volume used during UHPSFC-MS/MS analysis,
though it should be noted that an older generation mass spectrometer
was employed for the UHPLC-MS/MS analyses. More recent compar-
isons of the lower limit of quantiﬁcation (LLOQ) for 11‑oxygenated
androgens using the same mass spectrometer and MS settings revealed a
5- to 25-fold increase in sensitivity with UHPSFC-MS/MS, despite a 5-
fold lower injection volume [18,24].
The same MS settings are suitable for both UHPLC and UHPSFC,
with the ESI variables (desolvation temperature, desolvation gas ﬂow
and capillary voltage) having the greatest inﬂuence on UHPSFC-MS/MS
sensitivity [29]. Interestingly, intentionally using suboptimal settings
during UHPSFC-MS/MS reduced sensitivity 8- to 14-fold depending on
the analyte tested. Losses of 45- to 215-fold were observed during
UHPLC-MS/MS when the same optimal and suboptimal settings were
applied, with sensitivity dropping below the LLOQ for all analytes.
These results clearly show that in addition to oﬀering increased
K.-H. Storbeck et al. Journal of Chromatography B 1085 (2018) 36–41
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sensitivity, UHPSFC-MS/MS also provides robust sensitivity when
compared to UHPLC-MS/MS. Notably, in both cases changes in capil-
lary voltage had the smallest eﬀect on sensitivity, while desolvation gas
ﬂow and desolvation temperature both had a substantial eﬀect. This
ﬁnding further demonstrates the importance of the nebulization pro-
cess, which is clearly more eﬃcient during UHPSFC-MS/MS. This is
likely due to both the decompression of the CO2 and the absence or
reduced amount of water present in the mobile phase [29].
These beneﬁts have also been demonstrated for the analysis of
conjugated urinary metabolites [13]. Samples spiked with 1 ng/mL of
conjugated steroids (glucuronidated and sulphated) were easily quan-
tiﬁable by UHPSFC–MS/MS while approximately half of the tested
conjugated steroids were not detectable by UHPLC–MS/MS at these
levels. Moreover, the repeatability obtained using UHPSFC–MS/MS was
reported to be better than that obtained by UHPLC–MS/MS.
3.6. Under pressure?
Although a limited number of studies to date have clearly demon-
strated improved sensitivities and reduced matrix eﬀects with UHPSFC-
MS/MS as compared to UHPLC-MS/MS [29,32,33] this is not without a
caveat. First it should be noted that all direct comparisons of sensitivity
have been conducted using the same injection volume (typically 1 μL).
From our experience injection volumes>1–2 μL cause severe peak
broadening and increases in pressure during UHPSFC-MS/MS [26],
however, this can also be dependent on the width of the column. Some
of the diﬀerences in sensitivity can therefore be overcome by using
larger injection volumes (5–20 μL) which are better tolerated by
UHPLC-MS/MS. Furthermore, the maximum operating pressure for
UHPLC-MS/MS systems are usually in the region of 15,000 PSI. These
systems are therefore very robust when analysing samples originating
from complex biological matrixes such as serum which can lead to an
increase pressure over the course of an analysis batch. The maximum
operating pressure of our UHPSFC-MS/MS (Waters UPC2-MS/MS) is
6000 PSI and we have experienced problems with the system exceeding
the maximum pressure when analysing serum samples. Several factors
therefore need to be considered when developing methods for such
applications. First, the sample extraction method should be chosen to
reduce the complexity of the extracted sample and minimise compo-
nents which could contaminate the column and system. SLE or SPE
could likely yield better results in this regard than the liquid-liquid
extractions which we routinely employ when using UHPLC-MS/MS
[18,36]. Second, the amount of modiﬁer should be considered. We have
found that gradients up to 40–50% modiﬁer are required to elute some
steroids, but this comes at the cost of increased pressure. Third, the ﬂow
rate should be considered – while higher ﬂow rates reduce run times
and increase throughput they also increase the pressure. Slightly lower
ﬂow rates should therefore be considered during method development
to build in suﬃcient head room. Finally, the back-pressure regulator
setting needs to be considered. Higher settings can be attractive as they
increase chromatographic eﬃciency and reduce run times, but at the
cost of increased overall operating pressure.
3.7. Complex method development
The potential of UHPSFC-MS/MS cannot be disputed. The devel-
opment of suitable UHPSFC-MS/MS methods can, however, be more
complex than that of UHPLC-MS/MS methods due to an increased
number of variables which include stationary phase selection, modiﬁer
composition, ﬂow rate, gradient, back-pressure regulator setting, make-
up solvent and make-up ﬂow rate. A good sequence to follow is pre-
sented in [33]. Brieﬂy, a generic gradient can be used to compare dif-
ferent stationary phases. Methanol is a good modiﬁer to start with.
After identifying the best stationary phase, the same generic gradient
can be used to test the eﬀect of diﬀerent modiﬁers and modiﬁer ad-
ditives. Column temperatures also need optimisation as they can aﬀect
resolution. Once the best combination of stationary, mobile phase and
temperature have been identiﬁed, the gradient, ﬂow rate and back-
pressure regulator settings can be optimised individually. The make-up
solvent and ﬂow rate can subsequently be optimised.
3.8. Need for comprehensive cross validation with established methods/
reference standards
To move from a research tool to a clinical service is not an easy
route. As with all new technologies convincing clinical scientists of the
beneﬁts of changing established practice is challenging. The use of li-
quid chromatography mass spectrometry itself within the clinical la-
boratory is still relatively new, only being introduced over the last
10–20 years. Even with its many advantages mass spectrometry in a
clinical laboratory is still somewhat side-lined due to the ease and us-
ability of the large immunoassay analysers. This is, however, changing
with clinicians demanding accurate quantiﬁcation of multiple steroids
in short time periods, which is unachievable by immunoassay [4]. The
research environment has already accepted this, with mass spectro-
metry being recognised as the gold standard [2]. Nonetheless, the ad-
vantage must be clearly apparent before any MS based methodology is
adopted. This can only be proven through cross validation to reference
methods, where multiple samples are analysed and statistically corre-
lated against currently acceptable methods. There are a few studies
starting to complete this work for conventional UHPLC-MS/MS
[24,29,32,35], but none yet for UHPSFC-MS/MS. Furthermore, com-
prehensive method validation [37] and accreditation using reference
standards will be required before this technique is implemented in the
clinical laboratory.
4. Conclusions
Given the advantages of UHPSFC-MS/MS outlined above it is clear
that this technology oﬀers an alternative to GC–MS and UHPLC-MS/MS
in the clinical/research setting, possibly even bridging the gap between
these two mainstay techniques. While it may be presumptuous to think
that UHPSFC-MS/MS would ever replace GC–MS or UHPLC-MS/MS,
this technology does oﬀer an attractive orthogonal high throughput
alternative which is well suited to routine analysis of complex steroid
panels including applications such as urinary, serum and salivary
steroid proﬁling for diagnostics and monitoring. Indeed, the simpliﬁed
sample preparation and high throughput potential of this technique
may greatly improve diagnostics screening methods. This may be of
great value in the neonatal population as it is critically important to
obtain a diagnosis of any potential endocrine disorder as early as pos-
sible as these children can present with a life threatening adrenal crisis
if they are not started promptly on life-long and life-saving steroid
hormone replacement treatment. The ﬁrst presenting clue to a diagnosis
of an inborn steroidogenesis disorder can be ambiguous genitalia from
birth but patients can go on to develop adrenal crisis within the ﬁrst
two weeks of life. Unfortunately, with the limited availability of this
modality and the time it takes from sample collection to result, GC–MS
remains an inaccessible tool in the acute neonatal setting for clinicians.
Consequently the mainstay for diagnosis currently remains im-
munoassay which carries a high false positive rate, particularly in the
preterm and small for gestational age populations.
UHPSFC-MS/MS has also shown promise in the quantiﬁcation of
conjugated steroids, an aspect of steroid metabolomics that should
continue to be explored as this has the potential to further reduce
analysis times and cost [13]. As with any new technology only time and
usage will reveal the true potential, but based on results thus-far
UHPSFC-MS/MS has undisputedly opened new possibilities within the
ﬁeld of steroid analysis.
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